Published Date: 30 Sep 2024
News, features, and commentary about cancer-related issues
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Benjamin Tolchin, MD, MS, FAAN. [LISTEN TIME: 23 minutes]
Alixorexton, an oral investigational selective orexin 2 receptor agonist, is currently in development for the treatment of narcolepsy type 1 and type 2, and idiopathic hypersomnia.
1.
Hereditary cancer has a rare and underreported cause.
2.
When it comes to LBCL relapse in complete remission, ASCT outperforms CAR T-cell therapy.
3.
Large, Grade 4 Kidney Tumors Pose Risk of Early Cancer-Specific Mortality
4.
Exercise can counter detrimental effects of cancer treatment, review suggests
5.
Cancer Treatment Ups CV Risk; Therapy's Next Big Thing; Nude Photos Settlement
1.
Interpreting Iron Studies: What Your Blood Results Really Mean
2.
Exploring the Benefits of Endari: How This Natural Remedy Can Help You Live a Healthier Life
3.
Decoding the Future: Cancer Genomics and Radiomics in Oncology
4.
The Importance of Having a Quick and Effective Heparin Antidote
5.
The Immunotherapeutic and Targeted Revolution in Melanoma Management – A 2025 Perspective
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
3.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation